Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.

Teresa L KaufVimalanand Shrikant PrabhuGoran MedicRebekah H BorseBenjamin MillerJennifer GaultneyShuvayu S SenAnirban Basu

Published in: BMC infectious diseases (2017)

Model results show that ceftolozane/tazobactam is likely to be cost-effective compared with piperacillin/tazobactam for the empiric treatment of hospitalized cUTI patients in the United States.

Keyphrases

gram negative
urinary tract infection
end stage renal disease
multidrug resistant
public health
chronic kidney disease
stem cells
combination therapy
bone marrow
patient reported outcomes